This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
In introducing animal products into our therapeutic armamentarium we have also introduced opportunities for unintentional transmission of those diseases from which the animal furnishing the products may be suffering. This is a danger against which every precaution is taken by all who are engaged in the preparation of such biologic products, and the accidental transmission of disease by this method is, therefore, a most rare occurrence. The chief expense of such preparations as diphtheria antitoxin does not lie in the actual cost of producing the antitoxin, but in securing the absolute purity and safety of the product. It would be a simple matter to inject a horse with diphtheria toxin, draw off its blood and secure a large amount of an effective antitoxin at a very small cost. But it is the expert careand supervision, the skilled labor and the extensive animal experimentation that is required to insure the sterility
THE SAFEGUARDING OF BIOLOGIC THERAPEUTIC AGENTS. JAMA. 1908;L(12):965–966. doi:10.1001/jama.1908.02530380037008
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: